Genus plc (GENSF)
USD 21.01
(0.0%)
USD 21.01
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | 73.7 Million USD | -24.25% |
| 2023 | 97.3 Million USD | 10.67% |
| 2022 | 93.1 Million USD | -12.17% |
| 2021 | 95.4 Million USD | 23.9% |
| 2020 | 88.3 Million USD | 17.96% |
| 2019 | 41.7 Million USD | 4.87% |
| 2018 | 36.4 Million GBP | 1.49% |
| 2017 | 64.8 Million GBP | -33.78% |
| 2016 | 80 Million GBP | 64.15% |
| 2015 | 75.2 Million GBP | 40.88% |
| 2014 | 55 Million GBP | 25.0% |
| 2013 | 45.6 Million GBP | -49.39% |
| 2012 | 68 Million GBP | 63.82% |
| 2011 | 54.7 Million GBP | -3.85% |
| 2010 | 57.3 Million GBP | 23.81% |
| 2009 | 43 Million GBP | 6.94% |
| 2008 | 39.3 Million GBP | -4.21% |
| 2007 | 41.5 Million GBP | 124.38% |
| 2006 | 20.1 Million GBP | 38.73% |
| 2005 | 13.03 Million GBP | -1.8% |
| 2004 | 13.1 Million GBP | 8.26% |
| 2003 | 9.94 Million GBP | 1.12% |
| 2002 | 13.47 Million GBP | 2.51% |
| 2001 | 10.32 Million GBP | 20.28% |
| 2000 | 10.47 Million GBP | 47.38% |
| 1999 | 8.83 Million GBP | 10.85% |
| 1998 | 7.86 Million GBP | 27.35% |
| 1997 | 5.25 Million GBP | 1.12% |
| 1996 | 4.86 Million GBP | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 19.9 Million GBP | -66.57% |
| 2024 Q2 | 57.79 Million USD | 190.42% |
| 2024 FY | - USD | -48.95% |
| 2024 Q4 | 9.98 Million USD | 0.0% |
| 2023 Q2 | 45.11 Million USD | 59.4% |
| 2023 Q1 | 28.3 Million GBP | 72.04% |
| 2023 Q3 | 18.8 Million GBP | -58.32% |
| 2023 Q4 | 59.53 Million USD | 216.65% |
| 2023 FY | - USD | 10.67% |
| 2022 Q1 | 23.45 Million GBP | 60.62% |
| 2022 FY | - USD | -12.17% |
| 2022 Q3 | 16.45 Million GBP | -29.85% |
| 2022 Q2 | 23.45 Million USD | 0.0% |
| 2022 Q4 | 16.45 Million USD | 0.0% |
| 2021 FY | - USD | 23.9% |
| 2021 Q2 | 26.4 Million USD | 0.0% |
| 2021 Q1 | 26.4 Million GBP | 121.85% |
| 2021 Q4 | 14.6 Million USD | 0.0% |
| 2021 Q3 | 14.6 Million GBP | -44.7% |
| 2020 Q2 | 22.1 Million USD | 0.0% |
| 2020 Q4 | 11.9 Million USD | 0.0% |
| 2020 FY | - USD | 17.96% |
| 2020 Q1 | 22.1 Million GBP | -45.3% |
| 2020 Q3 | 11.9 Million GBP | -46.15% |
| 2019 Q1 | -7.65 Million GBP | -119.72% |
| 2019 Q3 | 40.4 Million GBP | 628.1% |
| 2019 FY | - USD | 4.87% |
| 2019 Q4 | 40.4 Million USD | 0.0% |
| 2019 Q2 | -7.65 Million GBP | 0.0% |
| 2018 Q1 | -7.55 Million GBP | -121.33% |
| 2018 Q2 | -7.55 Million GBP | 0.0% |
| 2018 FY | - GBP | 1.49% |
| 2018 Q3 | 38.8 Million GBP | 613.91% |
| 2018 Q4 | 38.8 Million GBP | 0.0% |
| 2017 Q4 | 35.4 Million GBP | 0.0% |
| 2017 FY | - GBP | -33.78% |
| 2017 Q1 | -5.95 Million GBP | -146.85% |
| 2017 Q2 | -5.95 Million GBP | 0.0% |
| 2017 Q3 | 35.4 Million GBP | 694.96% |
| 2016 FY | - GBP | 64.15% |
| 2016 Q4 | 12.7 Million GBP | 0.0% |
| 2016 Q3 | 12.7 Million GBP | -2.31% |
| 2016 Q2 | 13 Million GBP | 0.0% |
| 2016 Q1 | 13 Million GBP | 140.69% |
| 2015 FY | - GBP | 40.88% |
| 2015 Q3 | -31.95 Million GBP | -351.57% |
| 2015 Q1 | 12.7 Million GBP | 136.49% |
| 2015 Q2 | 12.7 Million GBP | 0.0% |
| 2015 Q4 | -31.95 Million GBP | 0.0% |
| 2014 Q4 | -34.8 Million GBP | 0.0% |
| 2014 FY | - GBP | 25.0% |
| 2014 Q3 | -34.8 Million GBP | -417.81% |
| 2014 Q2 | 10.95 Million GBP | 0.0% |
| 2014 Q1 | 10.95 Million GBP | -0.9% |
| 2013 Q2 | - GBP | 0.0% |
| 2013 FY | - GBP | -49.39% |
| 2013 Q4 | 11.05 Million GBP | 0.0% |
| 2013 Q3 | 11.05 Million GBP | 0.0% |
| 2012 Q2 | - GBP | 0.0% |
| 2012 FY | - GBP | 63.82% |
| 2011 FY | - GBP | -3.85% |
| 2011 Q2 | - GBP | 0.0% |
| 2010 FY | - GBP | 23.81% |
| 2010 Q2 | - GBP | 0.0% |
| 2009 FY | - GBP | 6.94% |
| 2009 Q2 | - GBP | 0.0% |
| 2008 Q2 | - GBP | 0.0% |
| 2008 FY | - GBP | -4.21% |
| 2007 Q2 | - GBP | 0.0% |
| 2007 FY | - GBP | 124.38% |
| 2006 FY | - GBP | 38.73% |
| 2006 Q1 | - GBP | 0.0% |
| 2005 FY | - GBP | -1.8% |
| 2005 Q1 | - GBP | 0.0% |
| 2004 Q1 | - GBP | 0.0% |
| 2004 FY | - GBP | 8.26% |
| 2003 FY | - GBP | 1.12% |
| 2002 FY | - GBP | 2.51% |
| 2001 FY | - GBP | 20.28% |
| 2000 FY | - GBP | 47.38% |
| 1999 FY | - GBP | 10.85% |
| 1998 FY | - GBP | 27.35% |
| 1997 FY | - GBP | 1.12% |
| 1996 FY | - GBP | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 203.75% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 1343.062% |
| SQZ Biotechnologies Company | -64.14 Million USD | 214.903% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 524.295% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 21.628% |
| Mesoblast Limited | -62.38 Million USD | 218.128% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 4898.024% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 1214.721% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 2177.813% |
| Marizyme, Inc. | -34.28 Million USD | 314.985% |
| ContraFect Corporation | -64.99 Million USD | 213.386% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 940.173% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 1728.299% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 5357.496% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 2886.971% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 3271.502% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 14326.536% |
| Accustem Sciences Inc. | -3.74 Million USD | 2067.212% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 252.819% |
| EV Biologics, Inc. | -1.26 Million USD | 5916.284% |
| Q BioMed Inc. | -617.62 Thousand USD | 12032.749% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | -1963.27% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 11753.906% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 3326.104% |
| Biomind Labs Inc. | -1.03 Million USD | 7223.877% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 9.87 Million USD | -646.178% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 1129.146% |
| Skye Bioscience, Inc. | -13.54 Million USD | 644.01% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 5054.915% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 294900.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 1997.372% |
| IMV Inc. | -35.52 Million USD | 307.469% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 564.406% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 3045.688% |
| GB Sciences, Inc. | -1.41 Million USD | 5290.561% |
| Alpha Cognition Inc. | -9.7 Million USD | 859.355% |
| HST Global, Inc. | -5303.00 USD | 1389879.37% |
| CSL Limited | 4.78 Billion USD | 98.461% |
| Halberd Corporation | -74.27 Thousand USD | 99320.506% |
| Enzolytics Inc. | -2.12 Million USD | 3573.091% |
| Resverlogix Corp. | -11.74 Million USD | 727.661% |
| Affymax, Inc. | -14.29 Million USD | 615.565% |
| SYBLEU INC | -141.57 Thousand USD | 52158.684% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 2506.125% |
| argenx SE | -216.02 Million USD | 134.117% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 233.179% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | -5955.875% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 5016.919% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | -19353.918% |
| AVAX Technologies, Inc. | -6.11 Million USD | 1305.698% |
| Zenith Capital Corp. | -8.6 Million USD | 956.379% |
| Genscript Biotech Corporation | -248.71 Million USD | 129.632% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 423152.638% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 3112.515% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 41969.205% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 285.938% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 2648.122% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 7143.788% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | -1095973.766% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 4311.431% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 3936.721% |
| BioStem Technologies, Inc. | -7.55 Million USD | 1075.688% |
| ONE Bio Corp. | 13.61 Million USD | -441.393% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 40798.445% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 3682.888% |
| Agentix Corp. | -1.37 Million USD | 5472.676% |
| LadRx Corporation | 412.28 Thousand USD | -17776.071% |
| Cell Source, Inc. | -4.27 Million USD | 1824.975% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 20169.658% |
| Regen BioPharma, Inc. | 1.46 Million USD | -4927.436% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 7965.956% |
| NovAccess Global Inc. | -1.03 Million USD | 7222.17% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | -732.411% |
| Itoco Inc. | -1.86 Million USD | 4043.296% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 19514.151% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 6703.943% |
| Kadimastem Ltd | -2.62 Million USD | 2908.281% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 30917.479% |
| CytoDyn Inc. | -18.02 Million USD | 508.786% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 93356.906% |
| Mobile Lads Corp. | -2.24 Million USD | 3388.477% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 602765.794% |
| Qrons Inc. | -40.08 Thousand USD | 183977.648% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 15274.663% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | -13873.339% |
| Rebus Holdings, Inc. | -951 Thousand USD | 7849.737% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 7039.671% |
| International Stem Cell Corporation | 202 Thousand USD | -36385.149% |
| Bioxytran, Inc. | -3.82 Million USD | 2029.245% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 140107.599% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 3093.584% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 305.47% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -45 Thousand USD | 163877.778% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 2791.746% |
| Neutra Corp. | -181.24 Thousand USD | 40762.742% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 465.594% |
| PureTech Health plc | -11.62 Million USD | 733.869% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 465.619% |
| IXICO plc | -707 Thousand USD | 10524.328% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 1059.011% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 252.443% |
| CSL Limited | 4.73 Billion USD | 98.443% |
| Cellectis S.A. | -92.63 Million USD | 179.559% |